NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

doi:10.4254/wjh.v6.i5.326

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6498)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-14) series.

Item

Count

PDF

370

WORD

312

HTML

2978

Figures (1-5)

250

Tables (1-14)

252

Sum=4162

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1049

Download

1287

Sum=2336

May 27, 2014 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326

Full Size Figure Download Figure

Figure 2 SVR rate after the lead-in period in patients with F3/4 fibrosis. PR: Conventional therapy (PEGylated interferon-α and ribavirin). ВOC RGT: Boceprevir-based, viral response-dependent triple therapy; BOC/PR48: Boceprevir-based triple therapy for 48 wk; the results are from the SPRINT-2 and RESPOND-2 studies.

Citation: Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J Hepatol 2014; 6(5): 326-339
URL: https://www.wjgnet.com/1948-5182/full/v6/i5/326.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i5.326